



March 9, 2022

BSE Limited
Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards, the Company having hosted an informative Facebook Live session with Mary Kom, on the occasion of International Women's Day, as a part of their Shakti campaign, designed to empower women in their fight against heart disease.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For LUPIN LIMITED



R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com

Lupin Teams up with Mary Kom to Raise Awareness Amongst Women on Cardiovascular Disease

Mumbai, India, March 09, 2022: On the occasion of International Women’s Day, global pharma major Lupin Limited (Lupin) hosted an informative Facebook Live session as a part of their **Shakti** campaign designed to empower women in their fight against heart disease. The session was organized to increase awareness of cardiovascular disease among women and to encourage more physician-patient interactions on the subject.

Speaking on the occasion, Mr. Rajeev Sibal, President - India Region Formulations, Lupin said, “Cardiovascular disease is the leading cause of death among women today. With timely intervention it can be prevented and that is our goal. Research shows that the death rate of cardiovascular diseases for women is higher compared to men. Yet the risk of heart diseases in women is still under-diagnosed and under-treated. Shakti is our initiative to empower women in their fight against heart disease and make their health a priority.”

The event also had three eminent cardiologists - Dr. Roxana Mehran from Mount Sinai, New York, Dr. Sarita Rao from Apollo Hospital, Indore and Dr. JPS Sawhney, from Sir Ganga Ram Hospital, Delhi. They touched upon the need to have a structured awareness initiative for elevating awareness around a healthy heart amongst women. They emphasized on early detection and screening tests as a way of life.

Lupin had earlier announced Mary Kom as the brand ambassador for its Shakti campaign. **Speaking about the event, six-time world boxing champion, Mary Kom said,** “Women are the backbone of society. They play multiple roles every day, right from taking care of their families to supporting them emotionally and financially. But in the process, they often forget to take care of their own health. I am delighted to be a part of this campaign. I hope together we will be able to motivate more women to take better care of their heart health and lead longer lives with their loved ones.”

The Facebook live session was attended by thousands of viewers from around the world.

Lupin’s Shakti campaign has been promoting awareness on heart diseases in women and has reached out to over 42,000 individuals and 10,000 healthcare professionals through interactive social media sessions, sharing informative videos from doctors, and in-clinic awareness activities.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com

Naini Thakkar

nainithakkar@lupin.com